Data as of Dec 06
| -0.0087 / -2.18%|
The 2 analysts offering 12-month price forecasts for Rexahn Pharmaceuticals Inc have a median target of 2.00, with a high estimate of 2.50 and a low estimate of 1.50. The median estimate represents a +411.12% increase from the last price of 0.39.
The current consensus among 2 polled investment analysts is to Buy stock in Rexahn Pharmaceuticals Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.